Proactive Investors - Run By Investors For Investors

Liberty Health Sciences opens first dispensary in South Florida

The new dispensary offers medical marijuana products and is located at 6827 Bird Road in Miami
Florida
Liberty is also boosting production capacity at its Liberty 360 plant in Gainesville, Florida

The Canadian cannabis company Liberty Health Sciences Inc (CSE:LHS) (OTCQX:LHSIF) on Tuesday opened its first South Florida dispensary in the center of Miami.

The new dispensary offers medical marijuana products and educational services and is located at 6827 Bird Road in Miami. It will be open from 10 a.m. to 7 p.m. on weekdays and will have slightly modified hours on weekends.

In addition to the Miami location, Liberty plans to open three more dispensaries in Florida this month and there will be more to come next year, pending approval by Florida’s Department of Health.

READ: Liberty Health Sciences signs deal to use AI-driven analytics to boost cannabis production

“Liberty remains committed to ensuring that its premium quality medical marijuana products and educational services are accessible to the more than 2.7 million people who call South Florida home,” said Liberty CEO George Scorsis in a statement.

To keep up with demand as it adds more dispensaries, Liberty is boosting production capacity at its Liberty 360 plant in Gainesville, Florida. The facility currently boasts 20,000 square feet of cultivation space and its next phase of 80,000 square feet is set to be completed by February.

Toronto-based Liberty has also improved its research and development capabilities at the Liberty 360 operation and continues to develop different formats and varieties of cannabis.

Liberty Health shares slipped by 1% to C$0.94 in Tuesday’s morning trading session.

Contact Ellen Kelleher at [email protected]

View full LHS profile View Profile

Liberty Health Sciences Timeline

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use